Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology

Clinica Chimica Acta

Volumn 389, Issue 1-2, 2008, Pages 87-92

  de Loor, Henriette ^a   Naesens, Maarten ^a   Verbeke, Kristin ^a   Vanrenterghem, Yves ^a   Kuypers, Dirk R ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Deproteinization; Drug stability; High performance liquid chromatography; Mycophenolate mofetil; Mycophenolic acid; Mycophenolic acid glucuronide

Indexed keywords

GLUCURONIDE; MYCOPHENOLIC ACID; PERCHLORIC ACID;

ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; ULTRAVIOLET RADIATION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PROTEINS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 38649102165     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.11.033     Document Type: Article

References (26)

1. Mele T.S., and Halloran P.F. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 47 (2000) 215-245
2. Bullingham R., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 64 (1998) 429-455
3. Mackenzie P.I. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 22 (2000) 10-13
4. Shipkova M., Strassburg C.P., Braun F., et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132 (2001) 1027-1034
5. Basu N.K., Kole L., Kubota S., and Owens I.S. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 32 (2004) 768-773
6. Picard N., Ratanasavanh D., Premaud A., Le Meur Y., and Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33 (2005) 139-146
7. Shipkova M., Armstrong V.W., Weber L.T., et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 24 (2002) 390-399
8. Shaw L.M., Korecka M., Venkataramanan R., Goldberg L., Bloom R., and Brayman K.L. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3 (2003) 534-542
9. Heller T., van Gelder T., Budde K., et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant 7 (2007) 1822-1831
10. Kuypers D.R.J., Claes K., Evenepoel P., et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 43 (2003) 866-880
11. Kuypers D.R.J., Vanrenterghem Y., Squifflet J., et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 25 (2003) 609-622
12. van Gelder T., Le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 (2006) 145-154
13. Shipkova M., Niedmann P.D., Armstrong V.W., et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 44 (1998) 1481-1488
14. Svensson J.O., Brattstrom C., and Sawe J. A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit 21 (1999) 322-324
15. Bolon M., Jeanpierre L., El B.M., Chelbi K., Sauviat M., and Boulieu R. HPLC determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma with hybrid material. J Pharm Biomed Anal 36 (2004) 649-651
16. Premaud A., Rousseau A., Le Meur Y., Lachatre G., and Marquet P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 26 (2004) 609-619
17. Annesley T.M., and Clayton L.T. Quantification of mycophenolic acid and glucuronide metabolite in human serum by HPLC-tandem mass spectrometry. Clin Chem 51 (2005) 872-877
18. Khoschsorur G., and Erwa W. Liquid chromatographic method for simultaneous determination of mycophenolic acid and its phenol- and acylglucuronide metabolites in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 799 (2004) 355-360
19. Ananias D., Golden D., Hoch D., Mountain L., Walker S., and Zhao Y. Evaluation of the Roche Mycophenolic Acid assay on the COBAS® c501 system. Ther Drug Monit 29 (2007) 512-513
20. Shipkova M., Schutz E., Armstrong V.W., Niedmann P.D., Oellerich M., and Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 46 (2000) 365-372
21. Baars B., van den Berg J., Janssen H.G., Schoenmakers P., Tijsen R., and Vonk N. Chromatografie in de praktijk: Monsterbewerking in de chromatografie (2000), ten Hagen & Stam b.v., Den Haag
22. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for industry. Analytical procedures and methods validation. Chemistry, manufacturing, and controls documentation (2000)
23. Stamm D. A new concept for quality control of clinical laboratory investigations in the light of clinical requirements and based on reference method values. J Clin Chem Clin Biochem 20 (1982) 817-824
24. Armbruster D., Tillman M., and Hubbs L. Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs. Clin Chem 40 (1994) 1233-1238
25. Shipkova M., Schneider T., Niedmann P.D., Schutz E., Wieland E., and Oellerich M. Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma. Clin Chem 45 (1999) 127-129
26. Shipkova M., Armstrong V.W., Oellerich M., and Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25 (2003) 1-16